Cargando…
A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants
In vivo T cell depletion with 100 mg alemtuzumab prevents graft‐versus‐host disease (GVHD) in reduced intensity conditioned transplants but is associated with delayed immune reconstitution, a higher risk of infection and relapse. De‐escalation studies have shown that a reduced dose of 30 mg is as ef...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737113/ https://www.ncbi.nlm.nih.gov/pubmed/25640315 http://dx.doi.org/10.1111/bjh.13239 |